Hypopharyngeal
cancer, a type
of head and neck cancer, develops in hypopharynx. Pharynx is a hollow tube
about five inches long, and the bottom part of the pharynx called hypopharynx.
Most of the hypopharyngeal malignancy occurs in squamous cells.
Some of the
major risk factors associated with the disease are smoking, heavy drinking,
tobacco consumption, Plummer-Vinson syndrome, and intake of nutrient deficit
diet. The signs and symptoms of the disease are ear pain, voice change, sore
throat, difficulty in swallowing, and lump in the neck.
Request to Get Free Sample Pages at:
Biotech
Pharmaceutical Co. Ltd. (BPL) is in the process of developing nimotuzumab as an
epidermal growth factor receptor antagonist for the treatment of hypopharyngeal
cancer. Novartis AG, and the Stanford University are also involved in
development of drugs for hypopharyngeal cancer.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment